PL01.03 Will the Immunotherapy with Newer Biomarkers, Combination Therapy or New Technology Eventually Cure Lung Cancer?doi:10.1016/j.jtho.2019.08.053T. MitsudomiJournal of Thoracic Oncology
Whilecurrent cancer treatments— surgery, radiation, chemotherapy, and immunotherapy — are generally effective. However, in some cases, their side effects may be significant. Scientists are now starting to use artificial intelligence (AI) and machine learning (ML) to formulate treatments that are jus...
Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing technology represents a significant breakthrough in personalized immunotherapy for human cancer. This strategy uses genetic modification to enable T cells to target tumor-specific antigens, attack specific cancer cells,...
The only chance of a cure is to diagnose lung cancer as early as possible. Early detection and the introduction of screening programs have the potential to fundamentally improve lung cancer healthcare. Although treatment for advanced tumor stages, such as immunotherapy, works well, it is also ver...
Autologous adoptive transfer of HIV-1-specific CD8+T cells is another way to directly enhance the CTL response of patients on cART. This strategy has been widely used in cancer immunotherapy [103–105]. Given that CD8+TCMcells possess the ability of self-renewal and maintain robust responses ...
Cervical cancer normally occurs in developing countries that lack the resources for screening. The development of alternative HPV vaccines that are low cost and heat stable will be important for the worldwide introduction of the vaccine. Approaches to needle-free vaccination are also being tested. ...
Importantly, checkpoint blockage, which is currently used for cancer immunotherapy, has been examined for HIV-1 treat- ment. Programmed cell death protein 1 (PD-1), a T cell surface receptor, is highly expressed on latently infected CD4+ or CD8+ T cells in patients treated with cART. High...
Early detection offers the best hope for a cure, but characteristics of this disease, such as... AM Lennon,CL Wolfgang,MI Canto,... - 《Cancer Research》 被引量: 148发表: 2014年 Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? With the ...
aBCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model. BCG斡旋的膀胱癌免疫疗法: 辨认治疗反应定列式使用一个被校准的数学模型。 [translate] abiannually for the second year 每年两次第二年 [translate] aCan I receive it tomorrow in...
it'll just increase the number of patients we can actually give an effective and curable treatment for large cell lymphoma, as the ultimate goal is to cure these patients because again, because of how this cancer behaves, patients cannot live with this cancer, so we have to get rid of it...